Get started
NN: Biggest daily H&S ever and €250 million new share buyback.After posting a more than 14% drop in 2022 operating profit (1.74bn), missing market estimates of 1.84 bn, and even though its operating capital generation (OCG) jumped 8% to 1.71 billion euros last year mainly thanks to higher interest rates and a strong business performance of the Netherlands Life and Insurance Europe segments; the company is shaping the biggest H&S pattern I have ever witnessed in a stock. Besides, NN also announced a new share buyback programme of 250 million euros. Will they implode due to share buybacks that will materialise into negative returns in the near future? At this pace, all those companies doing share buybacks will be the most damnified of the market due to an increased own capital at the wrong time. And it is a pity because this company has really attractive fundamentals, but after the operating profit miss in 2022 and the imminent recession all media is talking about, it is currently very risky to invest in it. But I will keep it in the radar as 35.6€ is the first support while 45€ is the first resistance.
EURONEXT:NNShort
by alexinve
Alfen May Collapse SoonThis chart could be a perfect example of why you should use caution when dealing with a volatile price chart. We’ve seen this with Bitcoin recently: The price goes up in a steady line, maybe in a parabolic fashion, before the trend weakens. A slowing down of a trend is not necessarily bad. For example: the price went up almost 30% between the first and the last sell signal (the ones at the top). However, it is clear that the price is struggling making more convincing highs. However, be cautious when you see this pattern at the top. A slowing down in a trend after the price went up exponentially is bad. That means that the buyers are exhausted. So to come back to this stock. The price went up exponentially, slowed down, went volatile, and now is below the resistance area. This convinces me that the price will go lower sooner or later. With charts like these, you could be looking at a drop of at least 40% to 50% from the current price.
EURONEXT:ALFENShort
by FetchTeam
LVMH BEARS ARE WAKING UP !"Companies like LVMH have high quality businesses, they compound profits over long periods of time and deliver great returns for shareholders," said Mark Denham, head of European equities at French asset manager Carmignac. "It is true that the ratings of these companies have risen so it becomes slightly more asymmetric, but over the long term earnings compounding is the dominant factor.” Aside from all above the ticket ti get into this market is getting way higher than it's value therefore a drope is both likely and possible. My own personal trade set up is shown on the chart , please feel free to share your comments .
EURONEXT:MCShort
by Crocobot
Sanofi S.A. (SAN.pa) bearish scenario:The technical figure Channel Up can be found in the daily chart in the French company Sanofi S.A. (SAN.pa). Sanofi S.A. is a French multinational pharmaceutical and healthcare company. Sanofi engages in the research and development, manufacturing and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines (it is the world's largest producer of the last through its subsidiary Sanofi Pasteur). The Channel Up broke through the support line on 24/01/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 26 days towards 86.54 EUR. According to experts, your stop-loss order should be placed at 92.90 EUR if you decide to enter this position. French drugmaker Sanofi SA plans to launch a drug for rare bleeding disorder hemophilia A this year, Chief Executive Officer Paul Hudson told CNBC in an interview last week. The U.S. Food and Drug Administration last year accepted the marketing application for the therapy, which is being developed in collaboration with Swedish drugmaker Sobi, and is expected to decide on an approval status by Feb. 28. Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. About 400 babies are born with this condition every year, although the exact number of people affected is not known, according to government data. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:SANShort
by legacyFXofficial